158 related articles for article (PubMed ID: 1556045)
1. Intravesical therapy.
Herr HW
Hematol Oncol Clin North Am; 1992 Feb; 6(1):117-27. PubMed ID: 1556045
[TBL] [Abstract][Full Text] [Related]
2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
3. Transurethral resection and intravesical therapy of superficial bladder tumors.
Herr HW
Urol Clin North Am; 1991 Aug; 18(3):525-8. PubMed ID: 1877115
[TBL] [Abstract][Full Text] [Related]
4. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
5. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A
Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
[TBL] [Abstract][Full Text] [Related]
6. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
Burk K; Kurth KH; Newling D
Prog Clin Biol Res; 1989; 303():423-34. PubMed ID: 2780657
[No Abstract] [Full Text] [Related]
7. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
9. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
[TBL] [Abstract][Full Text] [Related]
10. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
11. Management dilemmas in bladder cancer: radical TUR +/- systemic chemotherapy in the treatment of muscle-invasive bladder cancer.
Feneley MR; Mellon JK
Semin Urol Oncol; 2000 Nov; 18(4):300-7. PubMed ID: 11101094
[TBL] [Abstract][Full Text] [Related]
12. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
13. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
14. Re: Willem Oosterlinck,Richard Sylvester, Marco Babjuk, et al. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol 2011;59:374-6.
Gudjónsson S
Eur Urol; 2011 Jul; 60(1):e2-3; author reply e4. PubMed ID: 21531071
[No Abstract] [Full Text] [Related]
15. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
17. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
[TBL] [Abstract][Full Text] [Related]
18. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
19. Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
Dovedi SJ; Davies BR
Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963
[TBL] [Abstract][Full Text] [Related]
20. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin].
Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
